Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

医学 溃疡性结肠炎 内科学 胃肠病学 钙蛋白酶 炎症性肠病 耐受性 人口 不利影响 免疫学 疾病 环境卫生
作者
Silvio Danese,Maria Kłopocka,Ellen Scherl,Jacek A. Romatowski,Jessica Ravikoff Allegretti,Elena Peeva,Michael S. Vincent,Uwe Schoenbeck,Zhan Ye,Mina Hassan‐Zahraee,Natalie J. Rath,Gang Li,Srividya Neelakantan,Christopher R. Banfield,Christopher S. Lepsy,Deepa E. Chandra,Kenneth E. Hung
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:19 (11): 2324-2332.e6 被引量:110
标识
DOI:10.1016/j.cgh.2021.06.011
摘要

An immune component of inflammatory bowel disease is up-regulated tumor necrosis factor-like ligand 1A (TL1A). Anti-TL1A antibodies such as PF-06480605, a fully human immunoglobulin G1 monoclonal antibody, may have therapeutic potential.This Phase 2a, multicenter, single-arm, open-label study (TUSCANY) evaluated safety, tolerability, efficacy, pharmacokinetics, and immunogenicity in PF-06480605-treated participants with moderate to severe ulcerative colitis (UC). Participants received 500 mg intravenous PF-06480605 every 2 weeks, 7 doses total, with a 3-month follow-up period. Primary safety and efficacy endpoints were the incidence of adverse events (AEs) and week 14 endoscopic improvement (EI) (Mayo endoscopic subscore = 0 or 1), respectively. Secondary endpoints included total soluble TL1A (free/drug-bound) (sTL1A), incidence of anti-drug and neutralizing antibodies, PF-06480605 concentrations, and changes in fecal calprotectin and high-sensitivity C-reactive protein. Histology was assessed at week 14.The study enrolled 50 participants; 42 completed. Of 109 treatment-emergent AEs, 18 were treatment-related. The most common AEs were UC disease exacerbation and arthralgia (6 participants each). Four serious AEs, no deaths, and no malignancies were reported. Week 14 EI was observed in a statistically significant proportion of participants (38.2% [uniformly minimum-variance unbiased estimator, per protocol population]). Minimal histologic disease was observed after treatment (Robarts Histopathology Index ≤5: 33.3%; Geboes Index ≤3.2: 47.6%). sTL1A increase over time from baseline indicated sustained target engagement. Forty-one participants (82%) tested positive for anti-drug antibodies and 5 (10%) for neutralizing antibodies.PF-06480605 demonstrated an acceptable safety profile and statistically significant EI in participants with moderate to severe UC, warranting further study in a larger participant cohort. Tissue histopathology analyses support this conclusion.https://clinicaltrials.gov/NCT02840721.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai的应助被jerrychen采纳,获得10
刚刚
Jasper的应助被xiaomings007采纳,获得10
刚刚
1秒前
NexusExplorer的应助被煎饼煎饼采纳,获得10
1秒前
下一秒的王的应助被可靠吐司采纳,获得10
1秒前
curry完成签到,获得积分10
2秒前
xliang完成签到,获得积分10
2秒前
51515发布了新的文献求助10
2秒前
2秒前
彭于晏的应助被大刘采纳,获得10
2秒前
英姑的应助被yimeng采纳,获得10
3秒前
欢呼的梦蕊完成签到,获得积分10
3秒前
balalal发布了新的文献求助10
3秒前
3秒前
3秒前
爆米花的应助被11122采纳,获得10
3秒前
3秒前
4秒前
4秒前
4秒前
4秒前
缓慢半山发布了新的文献求助10
4秒前
知性的书文的应助被xh采纳,获得10
5秒前
柚一完成签到,获得积分10
5秒前
laruae发布了新的文献求助10
5秒前
6秒前
徐七鹏完成签到,获得积分20
6秒前
帅气皮皮虾完成签到,获得积分20
6秒前
6秒前
风趣之云完成签到 ,获得积分10
6秒前
热爱完成签到,获得积分10
6秒前
7秒前
科研通AI6.3的应助被知晏采纳,获得10
7秒前
7秒前
7秒前
小叶完成签到 ,获得积分10
7秒前
8秒前
风趣采白发布了新的文献求助10
8秒前
多情的土豆完成签到,获得积分10
8秒前
小白做科研完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522